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Jovani et al. October 2012 
. heightened immune activation in IBS + higher intestinal permeability 
. non-inflammatory factors such depression/stress might influence the immune 
system 
. inflammation cause or consequence? 
. immune system + integrity of IEB but role of brain-gut axis? 
>role of gut microbiome and small intestinal bacterial overgrowth (SIBO) + 
potential benefits of probiotics and rifaximin 
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We thank Dr. Jovani and colleagues for their comments regarding our review on 
associations between irritable bowel syndrome (IBS) and gut inflammation. 
Many studies have assessed inflammatory markersin IBS and yielded a considerable 
amount ofheterogeneous data, which made the link between IBS and inflammation 
difficult to evaluate. Thus, the aim of our review was to clarify this link by 
determining if the levels of inflammatory markers in fecal samples, blood samples or 
intestinal biopsies were higher in IBS patients than in healthy controls. 
Other risk factors such as stress and psychological factors are involved in IBS 
etiology1, however these were not described in detail since this was out of the scope 
of the present review. We also fully agree that alteration of the gut microflora can 
contribute to IBS etiopathogenesis.Actually, dysbiosis was quite consistently 
reported in IBS.2Small intestinal bacterial overgrowth (SIBO) has been somewhat 
associated with IBS3although the existence of acausal link between IBS and SIBO is 
still under debate because most of the existing studies are methodologically biased 
or lack the appropriate controls.4 
In line with a possible involvement of dysbiosis and/or SIBO in IBS, recent studies 
have shown beneficial effects of the antibiotics mesalazineand rifaximin on 
symptomatology.5Probiotics can relieve symptoms in some cases as 
well.6Nevertheless, large randomized and controlled trials are still needed to further 
evaluate the effectiveness of anti-inflammatory agents and probiotics for treating 
IBS.Associations between beneficial effects of antibiotics and presence of SIBO are 
lackingas well.2 Despite these shortcomings, modulation of the intestinal flora could 
indeed be a prosperous direction of future research. The pathophysiological 
consequences of these microflora changes in IBS are not well understood.However, 
one explanation could be the increase in intestinal permeability following alteration 
of tight junction complexes in intestinal epithelial cells and subsequent immune 
activation within the mucosa.7 
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